# PeptideScanner evidence objects: Motixafortide

Every published version of the records placed with Motixafortide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/motixafortide.json. Selected public evidence only; not medical advice.

- Objects: 17
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct04543071-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT04543071

> PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct04543071-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04543071-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct04543071-motixafortide-v1
- Content SHA-256: `217ead00a2cbc4bbc1031217a72bbf1c3614df3c117d007df05488efac3da0b8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04543071 ([`ctg-observation-nct04543071-2026-09-21-7862f0a88bf1`](#source-ctg-observation-nct04543071-2026-09-21-7862f0a88bf1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct04543071-2026-09-21-7862f0a88bf1`](#source-ctg-observation-nct04543071-2026-09-21-7862f0a88bf1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct04543071-2026-09-21-7862f0a88bf1`](#source-ctg-observation-nct04543071-2026-09-21-7862f0a88bf1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04543071-2026-09-21-7862f0a88bf1`](#source-ctg-observation-nct04543071-2026-09-21-7862f0a88bf1))

### Sources

<a id="source-ctg-observation-nct04543071-2026-09-21-7862f0a88bf1"></a>
- **ClinicalTrials.gov record NCT04543071 · retained source version 2026-09-21:7862f0a88bf1caf6146bcf84754fc641d45d1a2f3a281dd72e12c7d3e15f6b6d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04543071) (`ctg-observation-nct04543071-2026-09-21-7862f0a88bf1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04543071." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct04543071-motixafortide-v1 SHA-256: 217ead00a2cbc4bbc1031217a72bbf1c3614df3c117d007df05488efac3da0b8.

---

<a id="clinicaltrials-gov-nct05618301-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT05618301

> PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct05618301-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05618301-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct05618301-motixafortide-v1
- Content SHA-256: `5a5c9429767f6f10283d08f3da027d5150bb03a084df2be24274dec635d98a64`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05618301 ([`ctg-observation-nct05618301-2025-08-11-46d2cca30b6b`](#source-ctg-observation-nct05618301-2025-08-11-46d2cca30b6b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct05618301-2025-08-11-46d2cca30b6b`](#source-ctg-observation-nct05618301-2025-08-11-46d2cca30b6b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct05618301-2025-08-11-46d2cca30b6b`](#source-ctg-observation-nct05618301-2025-08-11-46d2cca30b6b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05618301-2025-08-11-46d2cca30b6b`](#source-ctg-observation-nct05618301-2025-08-11-46d2cca30b6b))

### Sources

<a id="source-ctg-observation-nct05618301-2025-08-11-46d2cca30b6b"></a>
- **ClinicalTrials.gov record NCT05618301 · retained source version 2025-08-11:46d2cca30b6b5a9c00327a8d79058b0641eac735c13ec25cf2298d0b11ed98c2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05618301) (`ctg-observation-nct05618301-2025-08-11-46d2cca30b6b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05618301." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct05618301-motixafortide-v1 SHA-256: 5a5c9429767f6f10283d08f3da027d5150bb03a084df2be24274dec635d98a64.

---

<a id="clinicaltrials-gov-nct06442761-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT06442761

> PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct06442761-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06442761-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06442761-motixafortide-v1
- Content SHA-256: `fd80f201528c172bcfd6710d5d137710c86d1f63a0c7b865b1f0bc0f6f92e87b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06442761 ([`ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6`](#source-ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6`](#source-ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6`](#source-ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6`](#source-ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6))

### Sources

<a id="source-ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6"></a>
- **ClinicalTrials.gov record NCT06442761 · retained source version 2026-09-08:d1dd4c1ff4d6a2c74426844240bd467d997ea6efa22020dd266b584be851b9cb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06442761) (`ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06442761." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06442761-motixafortide-v1 SHA-256: fd80f201528c172bcfd6710d5d137710c86d1f63a0c7b865b1f0bc0f6f92e87b.

---

<a id="clinicaltrials-gov-nct06506461-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT06506461

> PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct06506461-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06506461-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06506461-motixafortide-v1
- Content SHA-256: `1f6d378479f407ebe35ca942c96612c0fdc9ed2abfd9020bc02f7e80d8a99277`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06506461 ([`ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2`](#source-ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2`](#source-ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2`](#source-ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2`](#source-ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2))

### Sources

<a id="source-ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2"></a>
- **ClinicalTrials.gov record NCT06506461 · retained source version 2026-10-15:a31b8b04e5e2490afe251c9eddd6ca4d1e17ff3c75786e3c5ab1525f636e0cee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06506461) (`ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06506461." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06506461-motixafortide-v1 SHA-256: 1f6d378479f407ebe35ca942c96612c0fdc9ed2abfd9020bc02f7e80d8a99277.

---

<a id="clinicaltrials-gov-nct06547112-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT06547112

> PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct06547112-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06547112-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06547112-motixafortide-v1
- Content SHA-256: `0d5dd7ddd36ffd4d0836bf7ee82e2926b5fa4fc73777851f10b369702a396e34`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06547112 ([`ctg-observation-nct06547112-2025-08-29-4ed42583441f`](#source-ctg-observation-nct06547112-2025-08-29-4ed42583441f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct06547112-2025-08-29-4ed42583441f`](#source-ctg-observation-nct06547112-2025-08-29-4ed42583441f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct06547112-2025-08-29-4ed42583441f`](#source-ctg-observation-nct06547112-2025-08-29-4ed42583441f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06547112-2025-08-29-4ed42583441f`](#source-ctg-observation-nct06547112-2025-08-29-4ed42583441f))

### Sources

<a id="source-ctg-observation-nct06547112-2025-08-29-4ed42583441f"></a>
- **ClinicalTrials.gov record NCT06547112 · retained source version 2025-08-29:4ed42583441f2698fd97f5863ef39be495f089bf14d2ebd9b68449fb31e401af** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06547112) (`ctg-observation-nct06547112-2025-08-29-4ed42583441f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06547112." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06547112-motixafortide-v1 SHA-256: 0d5dd7ddd36ffd4d0836bf7ee82e2926b5fa4fc73777851f10b369702a396e34.

---

<a id="clinicaltrials-gov-nct07101445-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT07101445

> PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct07101445-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07101445-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07101445-motixafortide-v1
- Content SHA-256: `11e820fff698897018694eee1b8736b1f1ed51674e67a9753ab4c27687344adf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07101445 ([`ctg-observation-nct07101445-2026-07-23-1ae1329888f7`](#source-ctg-observation-nct07101445-2026-07-23-1ae1329888f7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct07101445-2026-07-23-1ae1329888f7`](#source-ctg-observation-nct07101445-2026-07-23-1ae1329888f7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct07101445-2026-07-23-1ae1329888f7`](#source-ctg-observation-nct07101445-2026-07-23-1ae1329888f7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07101445-2026-07-23-1ae1329888f7`](#source-ctg-observation-nct07101445-2026-07-23-1ae1329888f7))

### Sources

<a id="source-ctg-observation-nct07101445-2026-07-23-1ae1329888f7"></a>
- **ClinicalTrials.gov record NCT07101445 · retained source version 2026-07-23:1ae1329888f72decdc1d2285059622e40088d98969222424c8ebe99668e9b7fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07101445) (`ctg-observation-nct07101445-2026-07-23-1ae1329888f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07101445." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07101445-motixafortide-v1 SHA-256: 11e820fff698897018694eee1b8736b1f1ed51674e67a9753ab4c27687344adf.

---

<a id="clinicaltrials-gov-nct07392970-motixafortide-v1"></a>

## ClinicalTrials.gov record NCT07392970

> PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.

- Evidence object: `story:clinicaltrials-gov-nct07392970-motixafortide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07392970-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07392970-motixafortide-v1
- Content SHA-256: `0b0dfd93d2abb8140450502fccb5892ebe93b65ec23f3e910063e97343eac709`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07392970 ([`ctg-observation-nct07392970-2026-07-24-fee94029badb`](#source-ctg-observation-nct07392970-2026-07-24-fee94029badb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct07392970-2026-07-24-fee94029badb`](#source-ctg-observation-nct07392970-2026-07-24-fee94029badb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide. ([`ctg-observation-nct07392970-2026-07-24-fee94029badb`](#source-ctg-observation-nct07392970-2026-07-24-fee94029badb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07392970-2026-07-24-fee94029badb`](#source-ctg-observation-nct07392970-2026-07-24-fee94029badb))

### Sources

<a id="source-ctg-observation-nct07392970-2026-07-24-fee94029badb"></a>
- **ClinicalTrials.gov record NCT07392970 · retained source version 2026-07-24:fee94029badb26594534c702c6c4ea1df6e065cec1e928fcbc5375e29ec6076a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07392970) (`ctg-observation-nct07392970-2026-07-24-fee94029badb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07392970." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07392970-motixafortide-v1 SHA-256: 0b0dfd93d2abb8140450502fccb5892ebe93b65ec23f3e910063e97343eac709.

---

<a id="fda-drugs-nda217159-v1"></a>

## Drugs@FDA application NDA217159

> The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda217159:v1`
- Evidence domain: Regulatory
- Date in source: 2023-09-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda217159/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#fda-drugs-nda217159-v1
- Content SHA-256: `fcebc83bfc1bd1a00625b0fcc9b7824923afbe0666fd0502b33f27476f821052`

### Claims and source pins

#### Headline

Drugs@FDA application NDA217159 ([`fda-drugs-nda217159-2023-09-08-b15bf44a56da`](#source-fda-drugs-nda217159-2023-09-08-b15bf44a56da))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients. ([`fda-drugs-nda217159-2023-09-08-b15bf44a56da`](#source-fda-drugs-nda217159-2023-09-08-b15bf44a56da))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients. ([`fda-drugs-nda217159-2023-09-08-b15bf44a56da`](#source-fda-drugs-nda217159-2023-09-08-b15bf44a56da))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda217159-2023-09-08-b15bf44a56da`](#source-fda-drugs-nda217159-2023-09-08-b15bf44a56da))

### Sources

<a id="source-fda-drugs-nda217159-2023-09-08-b15bf44a56da"></a>
- **Drugs@FDA application NDA217159 · original submission status AP · 2023-09-08 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217159%22&limit=1) (`fda-drugs-nda217159-2023-09-08-b15bf44a56da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA217159." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#fda-drugs-nda217159-v1 SHA-256: fcebc83bfc1bd1a00625b0fcc9b7824923afbe0666fd0502b33f27476f821052.

---

<a id="pubmed-pmid-34253578-motixafortide-v1"></a>

## Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.

> PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34253578-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34253578-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-34253578-motixafortide-v1
- Content SHA-256: `6d0b3b75df5b52b4f8eca71c2cd6706c438eaa534e73ffafb19c3e2343eabb68`

### Claims and source pins

#### Headline

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. ([`pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db`](#source-pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db))

#### Summary

PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db`](#source-pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db))

#### Paragraph 1

PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db`](#source-pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db`](#source-pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db))

### Sources

<a id="source-pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db"></a>
- **Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. · retained source version 1:2022-04-01:current:1ac8436395db8f72e98b5c1b8f1bcbacfddd4c9bed28fa7db6a74c5286345267** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34253578/) (`pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-34253578-motixafortide-v1 SHA-256: 6d0b3b75df5b52b4f8eca71c2cd6706c438eaa534e73ffafb19c3e2343eabb68.

---

<a id="pubmed-pmid-36901829-motixafortide-v1"></a>

## Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.

> PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36901829-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-03-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36901829-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-36901829-motixafortide-v1
- Content SHA-256: `2e305d07d1ca4b5d1fbd6ab054156352894ee7af58d3ff5586a5d0cdbef2f63a`

### Claims and source pins

#### Headline

Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor. ([`pubmed-observation-pmid-36901829-2023-03-14-7816465e168a`](#source-pubmed-observation-pmid-36901829-2023-03-14-7816465e168a))

#### Summary

PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36901829-2023-03-14-7816465e168a`](#source-pubmed-observation-pmid-36901829-2023-03-14-7816465e168a))

#### Paragraph 1

PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36901829-2023-03-14-7816465e168a`](#source-pubmed-observation-pmid-36901829-2023-03-14-7816465e168a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36901829-2023-03-14-7816465e168a`](#source-pubmed-observation-pmid-36901829-2023-03-14-7816465e168a))

### Sources

<a id="source-pubmed-observation-pmid-36901829-2023-03-14-7816465e168a"></a>
- **Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor. · retained source version 1:2023-03-14:current:7816465e168a63a7f42c0d34cc30f50553a64def31e14466517c43c97fdd2670** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36901829/) (`pubmed-observation-pmid-36901829-2023-03-14-7816465e168a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-36901829-motixafortide-v1 SHA-256: 2e305d07d1ca4b5d1fbd6ab054156352894ee7af58d3ff5586a5d0cdbef2f63a.

---

<a id="pubmed-pmid-37069359-motixafortide-v1"></a>

## Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.

> PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37069359-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37069359-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37069359-motixafortide-v1
- Content SHA-256: `499a69353d02f88edc61d315066308670719df2daf837c69031cfe415104f6b2`

### Claims and source pins

#### Headline

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. ([`pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281`](#source-pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281))

#### Summary

PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281`](#source-pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281))

#### Paragraph 1

PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281`](#source-pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281`](#source-pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281))

### Sources

<a id="source-pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281"></a>
- **Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. · retained source version 1:2026-11-09:current:23b1564a2281305c6474597b6225a7f34d307ed0928a167a60175043c2bbef17** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37069359/) (`pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37069359-motixafortide-v1 SHA-256: 499a69353d02f88edc61d315066308670719df2daf837c69031cfe415104f6b2.

---

<a id="pubmed-pmid-37862457-motixafortide-v1"></a>

## Motixafortide Acetate.

> PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37862457-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37862457-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37862457-motixafortide-v1
- Content SHA-256: `e8947914519395f8c74209bfc9e4a69393ea41a6c28bc127018863b53e17e4d3`

### Claims and source pins

#### Headline

Motixafortide Acetate. ([`pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430`](#source-pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430))

#### Summary

PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430`](#source-pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430))

#### Paragraph 1

PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430`](#source-pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430`](#source-pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430))

### Sources

<a id="source-pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430"></a>
- **Motixafortide Acetate. · retained source version 1:2024-10-09:current:5a3c0499d430aadf43d28638c4786feaff5a89fcb1b76d5f1a31fdbc68143ba0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37862457/) (`pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Motixafortide Acetate." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37862457-motixafortide-v1 SHA-256: e8947914519395f8c74209bfc9e4a69393ea41a6c28bc127018863b53e17e4d3.

---

<a id="pubmed-pmid-38629183-motixafortide-v1"></a>

## A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.

> PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38629183-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38629183-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-38629183-motixafortide-v1
- Content SHA-256: `d931bc99ffc9065a01e5c125e088c8469c217e8937b397d215276efe9afd87cb`

### Claims and source pins

#### Headline

A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. ([`pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52`](#source-pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52))

#### Summary

PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52`](#source-pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52))

#### Paragraph 1

PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52`](#source-pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52`](#source-pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52))

### Sources

<a id="source-pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52"></a>
- **A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. · retained source version 1:2024-10-30:current:241b7d23cf528c17a5001110748a18b2737cf5fd5c56132f013aca51316f1e7f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38629183/) (`pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-38629183-motixafortide-v1 SHA-256: d931bc99ffc9065a01e5c125e088c8469c217e8937b397d215276efe9afd87cb.

---

<a id="pubmed-pmid-40420423-motixafortide-v1"></a>

## Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.

> PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40420423-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40420423-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-40420423-motixafortide-v1
- Content SHA-256: `12c915f001bcba800bc08cd4bfd9c7c66a353067b2828c8400f4446d4fe16597`

### Claims and source pins

#### Headline

Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma. ([`pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d`](#source-pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d))

#### Summary

PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d`](#source-pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d))

#### Paragraph 1

PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d`](#source-pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d`](#source-pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d))

### Sources

<a id="source-pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d"></a>
- **Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma. · retained source version 1:2025-05-27:current:65cc5143fe7da8368ee98228cb06ef9e226278692af862b31d737555f95588e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40420423/) (`pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-40420423-motixafortide-v1 SHA-256: 12c915f001bcba800bc08cd4bfd9c7c66a353067b2828c8400f4446d4fe16597.

---

<a id="pubmed-pmid-41741368-motixafortide-v1"></a>

## Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.

> PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41741368-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41741368-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-41741368-motixafortide-v1
- Content SHA-256: `b15bc82980fb1284ba9fda2e53207d2e3e7382fa9e4f21a79a9931871e515ea6`

### Claims and source pins

#### Headline

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. ([`pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c`](#source-pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c))

#### Summary

PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c`](#source-pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c))

#### Paragraph 1

PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c`](#source-pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c`](#source-pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c))

### Sources

<a id="source-pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c"></a>
- **Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. · retained source version 1:2026-08-13:current:3dca2b03912c56d85d44d318a88dbd4a4a2560315f1925a4585084912e8abeb3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41741368/) (`pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-41741368-motixafortide-v1 SHA-256: b15bc82980fb1284ba9fda2e53207d2e3e7382fa9e4f21a79a9931871e515ea6.

---

<a id="pubmed-pmid-42435378-motixafortide-v1"></a>

## Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.

> PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42435378-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42435378-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42435378-motixafortide-v1
- Content SHA-256: `6dd905b19fad54ce213b224f5e07e46876351e711b2d9ac0199b39c07aa9a463`

### Claims and source pins

#### Headline

Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience. ([`pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10`](#source-pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10))

#### Summary

PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10`](#source-pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10))

#### Paragraph 1

PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10`](#source-pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10`](#source-pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10))

### Sources

<a id="source-pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10"></a>
- **Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience. · retained source version 1:2026-07-11:current:1a6503110c10dd65b42f3d8f7ed3cab407b94dd5169fec82ecbb7fcffd0ce85c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42435378/) (`pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42435378-motixafortide-v1 SHA-256: 6dd905b19fad54ce213b224f5e07e46876351e711b2d9ac0199b39c07aa9a463.

---

<a id="pubmed-pmid-42811017-motixafortide-v1"></a>

## Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.

> PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42811017-motixafortide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42811017-motixafortide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42811017-motixafortide-v1
- Content SHA-256: `61733ba3a1de23184edbf8799c8333842b1e66fc871734801148eefdc2f3d508`

### Claims and source pins

#### Headline

Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. ([`pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996`](#source-pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996))

#### Summary

PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996`](#source-pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996))

#### Paragraph 1

PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996`](#source-pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996`](#source-pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996))

### Sources

<a id="source-pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996"></a>
- **Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. · retained source version 1:2026-11-09:current:09de67b6a9967635985784a3306de9f6908e8de9ba91b253ccc9fbb373ed3264** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42811017/) (`pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42811017-motixafortide-v1 SHA-256: 61733ba3a1de23184edbf8799c8333842b1e66fc871734801148eefdc2f3d508.

